Counterpoint: Should an attempt be made to withdraw inhaled corticosteroids in all patients with stable GOLD 3 (30% ≤ FEV1 < 50% predicted) COPD? No.
Inhaled corticosteroids (ICS) have been accepted by successive GOLD documents as being effective agents for the prevention of COPD exacerbations and decline in health status. The combination of an ICS and a long-acting beta-agonist (LABA) is superior to the LABA alone in achieving these positive ben...
第一著者: | Pavord, I |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
Elsevier
2018
|
類似資料
-
Inhaled corticosteroids in COPD.
著者:: Brightling, C, 等
出版事項: (1999) -
COPD: an inhaled corticosteroid-resistant, oral corticosteroid-responsive condition.
著者:: Saha, S, 等
出版事項: (2006) -
Inhaled corticosteroids in COPD (multiple letters) [1]
著者:: Hart, S, 等
出版事項: (1999) -
Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids
著者:: Siddiqui, S, 等
出版事項: (2018) -
The Use of Inhaled Corticosteroids to Prevent Acute Exacerbations of COPD: A Pro/Con Debate
著者:: Russell, R, 等
出版事項: (2019)